BioMark Aligns with National Strategy to Slash Lung Cancer Mortality with Next-Gen Liquid Biopsy

Rhea-AI Summary

BioMark Diagnostics (OTCQB: BMKDF) announced support for the 2026–2035 Pan-Canadian Lung Cancer Action Plan, aligning its next‑generation metabolomics and AI liquid biopsy approach with the plan's goal to reduce lung cancer mortality by 30% over the next decade. The company highlighted clinical results showing AI‑enabled biomarker testing can identify more early‑stage cancers, including in non‑smokers, and said its blood‑based tests can complement low‑dose CT screening and help expand access in underserved and remote communities.

BioMark invited partnerships with national and provincial healthcare providers and community organizations to scale early detection across Canada.

Next-generation metabolomics and AI technology supports the 2026 - 2035 Pan-Canadian Lung Cancer Action Plan's call to expand equitable access to life-saving early diagnosis

Vancouver, British Columbia--(Newsfile Corp. - November 12, 2025) - November is Lung Cancer Awareness Month, and BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy technologies for early cancer detection, is pleased to support the Canadian Cancer Society's national plan to reduce lung cancer mortality in Canada by 30% over the next decade.

The early detection activities and goals outlined in the 2026-2035 Pan-Canadian Lung Cancer Action Plan are highly aligned with BioMark's corporate mission of leading the world in early-stage cancer detection using metabolomics and artificial intelligence. This coordinated national effort recognizes that early detection is fundamental to saving lives and underscores the urgent need to expand access to innovative screening solutions across all Canadian communities.

"At BioMark, we believe that providing equitable, evidence-based access to early lung cancer detection will transform patient outcomes across Canada," said Rashid Bux, CEO and President, BioMark Diagnostics. "Our clinical results demonstrate the power of AI-enabled biomarker testing in identifying more early-stage cancers, even in non-smokers, directly supporting the Action Plan's commitment to saving lives nationwide. Our technology complements low-dose CT screening, addresses barriers in underserved and remote regions, and helps ensure that no Canadian is left behind in the fight against lung cancer."

The Action Plan also notes the need for innovative diagnostic tools and methods, like blood-based biomarker testing, to improve diagnostic accuracy and increase the likelihood of early-stage diagnosis. BioMark looks forward to collaborating with national partners, provincial healthcare providers, and community organizations to build capacity and make early lung cancer detection accessible, equitable, and effective across Canada. Healthcare providers and organizations interested in partnering to expand access to innovative early detection solutions are encouraged to contact BioMark.

About the Pan-Canadian Lung Cancer Action Plan
The 2026-2035 Pan-Canadian Lung Cancer Action Plan is a coordinated national strategy from the Canadian Cancer Society to reduce lung cancer mortality through improved prevention, early detection, treatment, and support. More information is available at: https://cancer.ca/en/about-us/lung-cancer-action-plan.

About BioMark Diagnostics Inc.

BioMark Diagnostics Inc. is a leading developer of liquid biopsy tests for the early detection of cancer that leverages the power of metabolomics and machine learning algorithms. The company's proprietary technology utilizes a simple blood draw to detect the presence of cancer-associated biomarkers, enabling earlier diagnosis and improved patient outcomes. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. BioMark is committed to developing innovative and accessible diagnostic solutions to address unmet medical needs in oncology.

Further information about BioMark is available under its profile on the SEDAR+ website www.sedarplus.ca and the CSE website https://thecse.com/.

For further information on BioMark, please Contact:
Rashid Ahmed Bux
President & CEO
BioMark Diagnostics Inc.
Tel. 604-370-0779
Email: info@biomarkdiagnostics.com

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events, or results or otherwise, other than as required by applicable securities laws.

The CSE has not reviewed, approved, or disapproved of the content of this press release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/274109

FAQ

What did BioMark (BMKDF) announce on November 12, 2025 about lung cancer screening?

BioMark said it supports the 2026–2035 Pan‑Canadian Lung Cancer Action Plan and highlighted its AI metabolomics liquid biopsy for earlier detection.

How does BioMark's BMKDF liquid biopsy relate to the Pan‑Canadian plan's 30% mortality reduction goal?

BioMark described its blood‑based biomarker testing as complementary to low‑dose CT and aimed at increasing early‑stage diagnosis to support the 30% reduction target.

Does BioMark claim its BMKDF test detects lung cancer in non‑smokers?

The company stated its clinical results show AI‑enabled biomarker testing can identify more early‑stage cancers, including cases in non‑smokers.

Will BioMark (BMKDF) partner with Canadian healthcare providers to expand access?

Yes; BioMark said it looks forward to collaborating with national partners, provincial healthcare providers, and community organizations to expand access.

Can BioMark's BMKDF test replace low‑dose CT screening?

BioMark positioned its blood‑based test as a complement to low‑dose CT screening, not a stated replacement.

How can healthcare organizations contact BioMark about partnerships after the November 12, 2025 announcement?

The company encouraged interested healthcare providers and organizations to contact BioMark to discuss partnering to expand early detection access.